A Phase 2 Study of Revumenib With Chemotherapy for Children with Recurrent or Persistent Infant Leukemia

Full Title

A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia (AALL2121) (CIRB)

Purpose

Researchers want to see how well revumenib works when given with chemotherapy to treat infant leukemia. The children in this study have acute leukemia that came back or keeps growing even after treatment. The leukemia has a gene rearrangement (genetic change) called KMT2A-R.

Revumenib targets the changes that occur in leukemia cells with a KMT2A rearrangement. It has been shown in laboratory studies to kill these cells.

If your child joins this study, they will sometimes take revumenib with chemotherapy and will sometimes take revumenib alone. Revumenib is taken orally (by mouth).

Contact

For more information and to see if your child can join this study, please call 1-833-MSK-KIDS.